deCODE genetics
  • HOME
  • COMPANY
    • ABOUT deCODE
    • MANAGEMENT
    • POLICIES
    • MEDIA RESOURCES
  • SCIENCE
  • PUBLICATIONS
  • NEWS
  • CAREERS
  • CONTACT
  • icelandic
Select Page

deCODE Discovers Common Genetic Variants Linked to Increased Risk of Breast Cancer

May 27, 2007 | NEWS

In a paper published today, a team of scientists from deCODE genetics (Nasdaq:DCGN) and academic colleagues from Europe and the United States report the discovery of two novel and very common genetic variants linked to susceptibility to breast cancer. The variants are...

deCODE Identifies Novel Genetic Variant Associated with Increased Risk of Heart Attack

May 3, 2007 | NEWS

Scientists at deCODE genetics (Nasdaq:DCGN) and academic colleagues from the United States today report the discovery of a common genetic variant that confers increased risk of myocardial infarction (MI), or heart attack. The variant, a SNP (a single-letter variant in...

deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack

May 1, 2007 | NEWS

deCODE genetics (Nasdaq:DCGN) today announced positive top-line results from its Phase I multiple dose clinical trial of DG051, which the company is developing for the prevention of heart attack. In the study, a randomized, double-blind, multi-dose, ascending dose,...

deCODE Launches deCODE T2™, a Novel DNA-based Test for Assessing Inherited Risk of Type 2 Diabetes

Apr 15, 2007 | NEWS

deCODE genetics, Inc. (Nasdaq:DCGN) today announced the launch of deCODE T2™, a novel DNA-based reference laboratory test for the first common and well-validated genetic risk factor for type 2 diabetes (T2D). deCODE believes this test may provide an important means to...

deCODE Discovers Second Major Prostate Cancer Risk Variant on Chromosome 8q24

Apr 1, 2007 | NEWS

First publication of genome-wide association study leveraging deCODE’s population approach; Finding to be integrated into deCODE’s DNA-based diagnostics program A team of deCODE scientists, along with academic colleagues from the United States, Iceland, Spain and the...

deCODE Initiates Phase I Clinical Program for DG051 for the Prevention of Heart Attack

Aug 14, 2006 | NEWS

deCODE genetics (Nasdaq:DCGN) today announced that it has begun enrolling patients in its Phase I clinical development program for DG051, the company’s follow-on developmental compound for the prevention of heart attack. The ascending-dose, double-blind, randomized,...
« Older Entries
Next Entries »

MORE ABOUT DECODE

  • MANAGEMENT
  • POLICIES
  • CAREERS
  • AVAILABLE POSITIONS
  • CONTACT
  • NEWS

ABOUT deCODE

  • HOME
  • COMPANY
    • ABOUT deCODE
    • MANAGEMENT
    • POLICIES
    • MEDIA RESOURCES
  • SCIENCE
  • PUBLICATIONS
  • NEWS
  • CAREERS
  • CONTACT
  • icelandic

MANAGEMENT

  • MANAGEMENT
  • POLICIES
  • CAREERS
  • AVAILABLE POSITIONS
  • CONTACT
  • NEWS

LATEST NEWS

  • Lethal mutations in pregnancy loss
  • DECODE ANNOUNCES NEW LEADERSHIP UPDATES 

ADDRESS

deCODE genetics
Sturlugata 8 | 101 Reykjavik
Iceland
Phone +354 570 1900

deCODE genetics | Sturlugata 8 | 101 Reykjavik | Iceland | phone +354 570 1900